Your browser doesn't support javascript.
loading
Tumor Location Is an Independent Prognostic Factor in Completely Resected Pathological Stage I Non-Small Cell Lung Cancer: A Multicenter Retrospective Study.
Kuo, Wei-Ke; Chen, Po-Ju; Wu, Mei-Hsuan; Lee, Hsin-Chung Henry; Fan, Jiun-Kai; Hsu, Pang-Hung; Weng, Ching-Fu.
Afiliación
  • Kuo WK; Division of Respiratory Therapy and Chest Medicine, Department of Internal Medicine, Sijhih Cathay General Hospital, New Taipei 221, Taiwan.
  • Chen PJ; Department of Bioscience and Biotechnology, National Taiwan Ocean University, Keelung 202, Taiwan.
  • Wu MH; Department of Thoracic Surgery, Sijhih Cathay General Hospital, New Taipei 221, Taiwan.
  • Lee HH; Center of Teaching and Research, Hsinchu Cathay General Hospital, Hsinchu 300, Taiwan.
  • Fan JK; Precision Medicine Ph.D. Program, National Tsing-Hua University, Hsinchu 300, Taiwan.
  • Hsu PH; Department of Surgery, Cathay General Hospital, Taipei 106, Taiwan.
  • Weng CF; Department of Diagnostic Radiology, Hsinchu Cathay General Hospital, Hsinchu 300, Taiwan.
Cancers (Basel) ; 16(9)2024 Apr 27.
Article en En | MEDLINE | ID: mdl-38730661
ABSTRACT
Previous studies suggested that the location of the primary tumor in non-small cell lung cancer (NSCLC) is associated with clinical features and prognosis, but results are conflicting. The purpose of this study was to explore tumor location as an independent risk factor of survival for patients with completely resected pathological stage I NSCLC. This was a multicenter retrospective study conducted in Taiwan. Included patients were diagnosed with stage I NSCLC and had undergone primary tumor resection. Variables including tumor location, pathological stage, histological differentiation, and International Association for the Study of Lung Cancer (IASLC) grade were evaluated for predictive ability for disease-free survival (DFS) and overall survival (OS). A total of 208 patients were included, with 123 (59.1%) patients having a primary tumor in the upper and middle lobes. The median duration of follow-up for survivors was 60.5 months. Compared to patients with IASLC Grade 3 disease, patients with Grade 1 disease had significantly longer DFS. Tumor location and IASLC grade were independent predictors for OS in multivariate analysis. Specifically, patients with NSCLC in the lower lobe and patients who are histologically classified as IASLC Grade 3 may have poorer prognosis and require greater attention to improve outcomes.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2024 Tipo del documento: Article País de afiliación: Taiwán

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2024 Tipo del documento: Article País de afiliación: Taiwán